alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 74, Number 24 (Friday, February 6, 2009)]
[Notices]
[Page 6272]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-2537]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Notice of Availability of Government-Owned Inventions; Available 
for Licensing

AGENCY: Department of the Army, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are assigned to the United States 
Government as represented by the Secretary of the Army. The inventions 
collectively enable a Tactical Biological Detector (TAC-BIO), and are 
made available for licensing by the Department of the Army. United 
States Patent Number 6,967,338 entitled ``Micro UV Particle Detector'', 
United States Patent Number 7,375,348 entitled ``Micro UV Detector'', 
Army Case Numbers; DAM 656-06 entitled ``Improved, Front-End Optics to 
the Micro UV Detector'', DAM 668-07 entitled ``Man Portable, Biological 
Aerosol Detector with High Level of Discrimination'', and DAM 689-08 
entitled ``Photon Counting Based Particle Detection Algorithm.''

ADDRESSES: Requests for data and inventor interviews should be directed 
to Eric McGill, telephone: 410-436-8467, <a href="/cdn-cgi/l/email-protection#f693849f95d885d89b95919f9a9ab68385d897849b8fd89b9f9a"><span class="__cf_email__" data-cfemail="e88d9a818bc69bc6858b8f818484a89d9bc6899a8591c6858184">[email protected]</span></a>, 
U.S. Army Edgewood Chemical Biological Center (ECBC), AMSRD-ECB-PI-BP-
TT, Bldg E3330/Rm 241 5183 Blackhawk Road, APG, MD 21010-5424. Requests 
should be made prior to February 20, 2009.

FOR FURTHER INFORMATION CONTACT: Dhirajlal Parekh, Office of Research 
and Technology Applications, U.S. Army Edgewood Chemical Biological 
Center, AMSRD-ECB-PI-BP-TT, Bldg E3330/Rm 241 5183 Blackhawk Road, APG, 
MD 21010-5424, telephone: 410-436-8400, e-mail: 
<a href="/cdn-cgi/l/email-protection#dabeb2b3a8bbb0b6bbb6f4aabba8bfb1b29aafa9f4bba8b7a3f4b7b3b6"><span class="__cf_email__" data-cfemail="0d6965647f6c67616c61237d6c7f6866654d787e236c7f607423606461">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION: The U.S. Army intends to move expeditiously 
to commercialize these patents by licensing to a cooperative research 
and development partner. Licensing application packages are available 
from ECBC and all applications and commercialization plans should be 
returned to ECBC by March 20, 2009. The Army intends to ensure that its 
licensed inventions are broadly commercialized throughout the United 
States.

    Authority: 35 U.S.C. 207, 37 CFR part 404.

Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. E9-2537 Filed 2-5-09; 8:45 am]
BILLING CODE 3710-08-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
#### Eduardo Perez GUTIERREZ; Rebeca Lopez Lopez, Petitioners, v. Alberto R. GONZALES, Attorney General, Respondent.

No. 05-70246.

United States Court of Appeals, Ninth Circuit.

Submitted Nov. 6, 2006.*

Filed Nov. 9, 2006.

*647Eduardo Perez Gutierez, Azusa, CA, pro se.

CAC-District Counsel, Esq., Office of the District Counsel Department of Homeland Security, Los Angeles, CA, Ronald E. Lefevre, Chief Counsel, Office of the District Counsel Department of Homeland Security, San Francisco, CA, John S. Hogan, Esq., U.S. Department of Justice, Civil Div./Office of Immigration Lit., Washington, DC, for Respondent.

Before: LEAVY, GOULD, and CLIFTON, Circuit Judges.

*

 The panel unanimously finds this case suitable for decision without oral argument. *See*Fed. R.App. P. 34(a)(2).

MEMORANDUM **

Eduardo Perez Gutierrez and Rebeca Lopez Lopez, husband and wife and natives and citizens of Mexico, petition pro se for review of the Board of Immigration Appeals’ order dismissing their appeal from an immigration judge’s decision denying their applications for cancellation of removal. To the extent we have jurisdiction it is under 8 U.S.C. § 1252. We deny in part, dismiss in part, and grant in part the petition for review, and remand for further proceedings consistent with this memorandum disposition.

Petitioners’ equal protection challenge to the constitutionality of the Nicaraguan Adjustment and Central American Relief Act is foreclosed by *Jimenez-Angeles v. Ashcroft,*291 F.3d 594, 602-03 (9th Cir.2002).

As to petitioner Rebeca Lopez Lopez only, we lack jurisdiction to review the agency’s determination that she did not establish the requisite hardship. *See*8 U.S.C. § 1252(a)(2)(B)©.

As to petitioner Eduardo Perez Gutierrez only, an intervening change in the law requires us to remand the case. It is not possible to determine from the record if his departure in 1998 was a border turnaround or an uninformed voluntary departure, as opposed to a knowing acceptance of administrative voluntary departure. In *Tapia v. Gonzales,*430 F.3d 997, 998 (9th Cir.2005), we “conclude[d] that being turned away at the border by immigration officials does not have the same effect as an administrative voluntary departure and does not itself interrupt the accrual of an alien’s continuous physical presence.” Similarly, in *Ibarra-Flores v. Gonzales,*439 F.3d 614, 619 (9th Cir.2006), we held that voluntary departure under threat of deportation breaks the accrual of continuous physical presence only where the alien is informed of and accepts the terms of the removal. Accordingly, we grant his petition for review and remand for further fact-finding consistent with *Tapia*and *Ibarra-Flores.*

Petitioners’ remaining contentions are without merit.

PETITION FOR REVIEW DENIED in part, DISMISSED in part, and GRANTED in part; REMANDED.

**

 This disposition is not appropriate for publication and may not be cited to or by the courts of this circuit except as provided by 9th Cir. R. 36-3.
**EXHIBIT      32**

**STATEMENT      REQUIRED BY 18 U.S.C. SECTION 1350,**

**AS      ADOPTED PURSUANT TO SECTION 906**

**OF      THE SARBANES-OXLEY ACT OF 2002**

| ·   | the                Report fully complies with the requirements of Section 13(a) or 15(d)                of                the Securities Exchange Act of 1934;                and |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | information                contained in the Report fairly presents, in all material respects,                the                financial condition and results of operations of the Company on the                dates                and for the periods presented. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **/s/                Ng Chi Shing**                         |
|-------------------------------------------------------------|
| Ng                Chi Shing                                 |
| Director,                President, Chief Executive Officer |
|                                                        |
| **/s/                Ng Chi Shing**                         |
| Ng                Chi Shing                                 |
| Chief                Financial Officer                      |
|                                                        |
| November 19,                2007                       |
**Exhibit 31.2****Sarbanes-Oxley Section 302 Certification**I, Gino Chouinard, certify that:1. I have reviewed this quarterly report on Form 10-Q of HearUSA, Inc.;2. Based on my knowledge, this report does not contain any untrue statement of a material fact oromit to state a material fact necessary to make the statements made, in light of the circumstancesunder which such statements were made, not misleading with respect to the period covered by thisreport;3. Based on my knowledge, the financial statements, and other financial information included inthis l report, fairly present in all material respects the financial condition, results ofoperations and cash flows of the registrant as of, and for, the periods presented in this report;4. The registrant’s other certifying officer and I are responsible for establishing and maintainingdisclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) forthe registrant and have: a) Designed such disclosure controls and procedures, or caused such disclosurecontrols and procedures to be designed under our supervision, to ensure that materialinformation relating to the registrant, including its consolidated subsidiaries, ismade known to us by others within those entities, particularly during the period inwhich this report is being prepared;  b) Evaluated the effectiveness of the registrant’s disclosure controls andprocedures and presented in this report our conclusions about the effectiveness of thedisclosure controls and procedures, as of the end of the period covered by this reportbased on such evaluations; and  c) Disclosed in this report any change in the registrant’s internal control overfinancial reporting that occurred during the registrant’s most recent fiscal quarter(the registrant’s fourth fiscal quarter in the case of an annual report) that hasmaterially affected, or is reasonably likely to materially affect, the registrant’sinternal control over financial reporting; and5. The registrant’s other certifying officer and I have disclosed, based on our most recentevaluation of internal control over financial reporting, to the registrant’s auditors and the auditcommittee of registrant’s board of directors (or persons performing the equivalent function): a) All significant deficiencies and material weaknesses in the design or operationof internal control over financial reporting which are reasonably likely to adverselyaffect the registrant’s ability to record, process, summarize and report financialinformation; and  b) Any fraud, whether or not material, that involves management or other employeeswho have a significant role in the registrant’s internal control over financialreporting.Date: August 11, 2005   /s/Gino Chouinard   Gino Chouinard  Chief Financial Officer
Exhibit 10.1
 BIOCLINICA, INC.
2010 STOCK INCENTIVE PLAN
 ARTICLE ONE
 GENERAL PROVISIONS
 I. PURPOSE OF THE PLAN
    II. STRUCTURE OF THE PLAN
  III. ADMINISTRATION OF THE PLAN
  1




---



##### 



provided,
however,
    IV. ELIGIBILITY
      2




---



##### 



V. STOCK SUBJECT TO THE PLAN
       3




---



##### 



4




---



##### 



ARTICLE TWO
 DISCRETIONARY GRANT PROGRAM
 I. OPTION TERMS
 provided, however
 Exercise Price.
       Exercise and Term of Options
 5




---



##### 



Effect of Termination of Service
       6




---



##### 



Stockholder Rights
 Repurchase Rights lower
 Transferability of Options
 Incentive Options
 7




---



##### 



Non-Statutory Options
 Beneficiary Designations
 Incentive Options
 Eligibility
 Dollar Limitation
  10% Stockholder
 II. STOCK APPRECIATION RIGHTS
 Authority.
 8




---



##### 



Types
 Tandem Rights
   Stand-Alone Rights
     9




---



##### 



Post-Service Exercise
 III. CHANGE IN CONTROL
     10




---



##### 



IV. PROHIBITION ON REPRICING PROGRAMS
  11




---



##### 



V. STOCK ISSUANCE TERMS
    12




---



##### 



lower
    13




---



##### 



VI. CASH INCENTIVE AWARDS AND DIVIDEND EQUIVALENT RIGHTS
 provided however,
   14




---



##### 



Dividend Equivalent Rights provided however
     15




---



##### 



Change in Control
 16




---



##### 



ARTICLE THREE
 MISCELLANEOUS
 I. TAX WITHHOLDING
   Stock Withholding
 Stock Delivery
 II. SHARE ESCROW/LEGENDS
  III. EFFECTIVE DATE AND TERM OF THE PLAN
  17




---



##### 



IV. AMENDMENT OF THE PLAN
   V. USE OF PROCEEDS
  VI. REGULATORY APPROVALS
  18




---



##### 



VII. NO EMPLOYMENT/SERVICE RIGHTS
  19




---



##### 



APPENDIX
  Award
 Board
 Change in Control
    Code
 Common Stock
 Compensation Committee
 Corporation




---



##### 



Discretionary Grant Program
 Employee
 Exercise Date
 Fair Market Value
   Family Member
 Incentive Option
 Involuntary Termination




---



##### 



Misconduct
 1934 Act
 Non-Statutory Option
 Optionee
 Parent
 Participant
 Permanent Disability or Permanently Disabled
 Plan
 Plan Administrator
 Plan Effective Date




---



##### 



Secondary Board Committee
 Section 16 Insider
 Service
 Stock Exchange
 Subsidiary
 10% Stockholder
 Withholding Taxes
II 

111TH CONGRESS 

1ST SESSION S. 2683 

To suspend temporarily the duty on Pyrasulfotole. 

IN THE SENATE OF THE UNITED STATES 

NOVEMBER 2, 2009 

Mr. BURR introduced the following bill; which was read twice and referred to 

the Committee on Finance 

A BILL 

To suspend temporarily the duty on Pyrasulfotole. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. PYRASULFOTOLE. 

4 (a) IN GENERAL.—Subchapter II of chapter 99 of 

5 the Harmonized Tariff Schedule of the United States is 

6 amended by inserting in numerical sequence the following 

7 new heading: 

‘‘ 9902.01.00 5-Hydroxy-1,3- 

dimethylpyrazol-4-yl 2-mesyl4-(trifluoromethyl)phenyl ketone (Pyrasulfotole) (CAS 

No. 365400–11–9) (provided 

for in subheading 

2933.19.23) ....................... Free No change No change On or before 

12/31/2011 ’’. 


hsrobinson on DSK69SOYB1PROD with BILLS
2 

•S 2683 IS

1 (b) EFFECTIVE DATE.—The amendment made by 

2 subsection (a) applies to goods entered, or withdrawn from 

3 warehouse for consumption, on or after the 15th day after 

4 the date of the enactment of this Act. 

Æ 


hsrobinson on DSK69SOYB1PROD with BILLS
CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002




       In connection  with the Annual Report of London  Pacific Group Limited on
Form  10-K  for the  period  ended  December  31,  2002 as  filed  with the U.S.
Securities and Exchange  Commission  (the  "Report"),  I, Arthur I. Trueger,  as
Executive Chairman of the registrant certify, pursuant to 18 U.S.C. ss. 1350, as
adopted by ss. 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

       (1) The  accompanying  Annual Report fully complies with the requirements
of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and

       (2) The  information  contained  in the Report  fairly  presents,  in all
material  respects,  the  financial  condition  and results of operations of the
registrant.



Date:  March 19, 2003                            By:    /s/  Arthur I. Trueger
                                                        Arthur I. Trueger
                                                        Executive Chairman
[Federal Register Volume 74, Number 203 (Thursday, October 22, 2009)]
[Notices]
[Page 54571]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-25374]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Notice of Establishment

    Pursuant to the Federal Advisory Committee Act, as amended (5 
U.S.C. Appendix 2), the Director, National Institutes of Health (NIH), 
announces the establishment of the Interdisciplinary Molecular Sciences 
and Training Integrated Review Group, (IRG).
    The IRG shall advise the Director, National Institutes of Health 
(NIH), and the Director, Center for Scientific Review (CSR), on the 
scientific and technical merit of applications for grants-in-aid for 
research, research training or research-related grants and cooperative 
agreements, or contract proposals relating to scientific areas relevant 
to biological chemistry, biophysics and cell biology, drug discovery 
and development, devices and detection systems, biomaterials, delivery 
systems and nanotechnology, computational biology, imaging and data 
mining, genes, genomes and genetics, environmental monitoring, and 
basic translational oncology.
    Duration of this committee will be continuing with no specified end 
date.

    Dated: October 9, 2009.
Francis S. Collins,
Director, National Institutes of Health.
[FR Doc. E9-25374 Filed 10-21-09; 8:45 am]
BILLING CODE 4140-01-M
EXHIBIT 32.1





CERTIFICATION PURSUANT TO


18 U.S.C. SECTION 1350


AS ADOPTED PURSUANT TO


SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002





In connection with the Quarterly Report of Columbia Laboratories, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2010 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Frank C. Condella, Jr., President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:





(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and





(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.








/s/ Frank C. Condella, Jr.


Frank C. Condella, Jr.


President and Chief Executive Officer


August 5, 2010
TERRY WAYNE BUSLER,

Appellant,

v.

STATE OF FLORIDA,

Appellee.

IN THE DISTRICT COURT OF APPEAL

FIRST DISTRICT, STATE OF FLORIDA

NOT FINAL UNTIL TIME EXPIRES TO 

FILE MOTION FOR REHEARING AND 

DISPOSITION THEREOF IF FILED

CASE NO. 1D14-3572

_____________________________/

Opinion filed August 12, 2016.

An appeal from the Circuit Court for Duval County.

James L. Harrison, Judge.

Nancy A. Daniels, Public Defender, and Megan Long, Assistant Public Defender, 

Tallahassee, for Appellant.

Pamela Jo Bondi, Attorney General, and Thomas H. Duffy, Assistant Attorney 

General, Tallahassee, for Appellee.

PER CURIAM.

AFFIRMED.

ROWE, KELSEY, and JAY, JJ., CONCUR.
#### FG HEMISPHERE ASSOCIATES LLC, Plaintiff-Appellee v. REPUBLIQUE DU CONGO, Defendant-Appellant CMS Nomeco Congo Inc; Nuevo Congo Co; Nuevo Congo Ltd, Garnishees-Appellants.

No. 06-20030.

United States Court of Appeals, Fifth Circuit.

Decided Dec. 18, 2006.

Dillon James Ferguson, Andrews & Kurth, Andrew L. Jefferson, Jr., Jefferson & Mims, Houston, TX, Bradford A. Berenson, Sidley Austin, Washington, DC, Robert Nathan Hochman, Kristen R. Seeger, Sidley Austin, Chicago, IL, for PlaintiffAppellee.

Guy Stanford Lipe, Vinson *&*Elkins, Houston, TX, for Garnishees-Appellants.

Before JOLLY, DENNIS, and CLEMENT, Circuit Judges.1

1

. Pursuant to 5th Cir. R. 47.5, the Court has determined that this opinion should not be published and is not precedent except under the limited circumstances set forth in 5th Cir. R. 47.5.4.

PER CURIAM:

IT IS ORDERED that appellee’s unopposed motion to remand this case to the United States District Court for the South*510ern District of Texas, Houston, is GRANTED.

IT IS FURTHER ORDERED that appellee’s unopposed motion requesting this Court to enter an order reversing the district court’s orders of 9/15/05 is GRANTED.

IT IS FURTHER ORDERED that appellee’s unopposed motion directing the district court to dissolve those writs of garnishments is GRANTED.
#### The People of the State of New York, Respondent, v Darryl Robinson, Appellant.

Submitted July 6, 2010;

decided August 26, 2010

Motion for an extension of the time within which to apply for permission to appeal pursuant to CPL 460.20 granted and motion papers treated as a timely CPL 460.20 application.
```

[Congressional Bills 111th Congress]
[From the U.S. Government Publishing Office]
[S. 2555 Introduced in Senate (IS)]

111th CONGRESS
  1st Session
                                S. 2555

        To extend the temporary suspension of duty on N-[[(4,6-
      dimethoxypyrimidin-2-yl)amino]carbonyl]-3-(ethylsulfonyl)-2-
             pyridinesulfonamide and application adjuvants.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                            October 30, 2009

  Mr. Burris introduced the following bill; which was read twice and 
                  referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL

 
        To extend the temporary suspension of duty on N-[[(4,6-
      dimethoxypyrimidin-2-yl)amino]carbonyl]-3-(ethylsulfonyl)-2-
             pyridinesulfonamide and application adjuvants.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. N-[[(4,6-DIMETHOXYPYRIMIDIN-2-YL)AMINO]CARBONYL]-3-
              (ETHYLSULFONYL)-2-PYRIDINESULFONAMIDE AND APPLICATION 
              ADJUVANTS.

    (a) In General.--Heading 9902.33.60 of the Harmonized Tariff 
Schedule of the United States (relating to mixtures of N-[[(4,6-
dimethoxypyrimidin-2-yl)amino]-carbonyl]-3-(ethylsulfonyl)-2-
pyridinesulfonamide and application adjuvants) is amended by striking 
``12/31/2009'' and inserting ``12/31/2011''.
    (b) Effective Date.--The amendment made by subsection (a) applies 
with respect to goods entered, or withdrawn from warehouse for 
consumption, on or after the 15th day after the date of the enactment 
of this Act.
                                 <all>
```